Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following Zevalin consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieved a response to first line therapy over chemotherapy alone. Additionally, Zevalin consolidation did not adversely affect the use of various effective second-line treatments including stem cell transplants in patients who relapsed.

"The FIT study follow-on results are quite impressive when one considers that the median progression free survival for the Zevalin recipients that achieved a complete remission (CR) after induction therapy has not yet been reached with an estimated 67 months compared to 30 months with chemotherapy alone," said James A. Bianco, M.D., CEO of Cell Therapeutics. "A single dose of consolidation that could allow patients with a CR from requiring additional treatment for their NHL for over 3 years represents a significant advancement in the treatment of this disease."

The multinational, randomized phase III FIT study evaluated the benefit and safety of a single infusion of Zevalin in patients with follicular B-cell non-Hodgkin's lymphoma who had achieved a partial remission (PR) or a complete remission / complete remission unconfirmed (CR/CRu) after receiving standard first-line chemotherapy regimens. Patients were randomized to either Zevalin consolidation or no further therapy. The FIT trial results were first presented at the December 2007 ASH annual meeting. The results were subsequently published in Journal of Clinical Oncology 2008 26(32):5156-64. At the 2008 ASH meeting, the investigators prese
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and Minimally ... medical device company, have formally agreed to an exclusive ... in Japan . It is anticipated that ... in the latter half of 2015. ... in endoscopic surgery market in Japan . ...
(Date:8/22/2014)...  Mark Riccio, director of Cornell University,s multi-scale ... the online crowd-funding platform Kickstarter to bring non-invasive ... and would-be superheros everywhere: "for FREE." Riccio,s campaign, ... if you had Superman,s X-ray vision?" The campaign ... from elementary through high school students, academic institutions, ...
(Date:8/22/2014)... 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... trading on The NASDAQ Stock Market under the ticker ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Systems, Inc. , the maker of TrackWise ... in enterprise quality and compliance management solutions, today ... provider of high-quality generic pharmaceuticals, has selected TrackWise® ...   As the manufacturer of more ...
... for Full Year Fiscal 2010 -- WEIFANG, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
Cached Medicine Technology:Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 2Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 3Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 4Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 2Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 3Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 4Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 5Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 6Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 7Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 8Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 9
(Date:8/22/2014)... The improved access to antiretroviral drugs ... developing world, has led to the decline in the ... due to AIDS globally. However, despite the fact that ... patients becoming affected by the virus is on the ... all related organisations and stakeholders, by 2015, significant investments ...
(Date:8/22/2014)... A national leader in home delivery of ... room to grow. , Headquarters for the provider of sterile-use ... building at 8516 N.W. Expressway in Oklahoma City. , ... Oklahoma’s best places to work by OKCBiz magazine – demanded ... 120 in the past two years, and staff count grew ...
(Date:8/22/2014)... 2014 (HealthDay News) -- People who use reduced-nicotine cigarettes ... levels of nicotine, according to a new study. ... other smokers, the researchers say. The month-long study ... smoked regular cigarettes with nicotine emission levels of 1.2 ... switched to reduced-nicotine cigarettes for the next three weeks. ...
(Date:8/22/2014)... years, several breakthrough treatments have become available for ... benefit from these treatments can be pre-identified by ... For example, patients whose lung cancer is driven ... benefit from the drug crizotinib, which targets this ... to replicate this success by matching different drugs ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ticket Down ... tickets in Kalamazoo, New Orleans, Albuquerque and Rapid City. ... the “Long Island Medium,” Theresa Caputo, allows just that. Caputo ... She is part of a close knit family who began ... with a spiritual healer, realized she had a chance to ...
Breaking Medicine News(10 mins):Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2
... Champions Gupta,s Commitment to Enriching Quality of Life Through ... American Council on Exercise (ACE), America,s leading authority on ... and training organizations in the world, today announced its ... , chief medical correspondent for the health and medical ...
... Emerson Network Power, a business of Emerson and the global ... its DA12-M series wall mount switching adapters, designed specifically for ... ... Carlsbad, CA (PRWEB) January 27, 2009 -- ...
... Consultants announced today,that its annual long-term care insurance training ... TN. , "This is THE ... is,100% sales training from the nation,s leading LTCI sales ... VP of Marketing. "The,primary focus of this seminar ...
... San Antonio -- The University of Texas at San ... status. UTSA,s College of Engineering has been awarded a ... to study energy combustion. , "This is one of ... study clean combustion, gasification and energy efficiency," said Efstathios ...
... CORONA DEL MAR, Calif., Jan. 27 Dr. ... technique in 1992 and has been successfully educating ... since. Dr. Friedberg has received a Congressional award ... the U.S. military in Iraq and Afghanistan. Benefits: ...
... real cost of the procedure beyond the initial price of surgery. ... of choosing a cosmetic surgeon wisely based on credentials, certification, and understanding, ... ... 2009 - You may be under the mistaken notion that because breast ...
Cached Medicine News:Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Emerson Network Power Introduces High Density AC-DC Adapters for Medical Applications 2Health News:Emerson Network Power Introduces High Density AC-DC Adapters for Medical Applications 3Health News:Phyllis Shelton's LTCI Sales Skills Seminar a Must-Attend Event for Insurance Professionals 2Health News:UTSA receives federal funding for fossil fuel research 2Health News:Cosmetic Surgery - PK 'Goldilocks' Anesthesia: All of the Benefits, None of the Risks 2Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 2Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 3Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: